|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Groupe Rein et Hypertension, 2 Laboratoire de Nutrition et Athérogénèse, Institut Universitaire de Recherche Clinique, Université Montpellier I, 34 093 Montpellier, France
| |
ABSTRACT |
|---|
|
|
|---|
The influence of a low-sodium (LS) diet
was assessed on the cardiac and renal alterations and pro-oxidant
effect associated with a 10-day infusion of angiotensin II (200 or 400 ng · kg
1 · min
1,
osmotic pumps). Tail-cuff pressure (TCP), albuminuria, and renal blood
flow were determined at the end of the experiments. Heart weight index
(HWI) and production of superoxide anion (O

heart weight; albuminuria; reactive oxygen species; renal hemodynamic
| |
INTRODUCTION |
|---|
|
|
|---|
THE DEVELOPMENT OF cardiac hypertrophy results from the interaction between several factors, including elevated arterial pressure, angiotensin II (ANG II), and sodium intake. Although blood pressure is an important determinant of cardiac mass (8), ANG II may directly increase protein synthesis and cause myocyte hypertrophy, as reported in cultured cardiac myocytes isolated from chicks (2) and neonatal rats (34). In vivo long-term administration of an initially subpressor dose of ANG II, a model that mimics the development of human hypertension, induces a gradual rise in blood pressure associated with a cardiac hypertrophy (7, 14, 17). However, ANG II might increase cardiac mass independently of arterial pressure. This was suggested by the presence of cardiac hypertrophy in rats infused with a nonpressor dose of the peptide (4, 37) or in rats infused with a pressor dose of ANG II and concomitantly treated by hydralazine (7, 37).
The concentration of sodium ion in vitro or dietary sodium intake in vivo may modulate cardiac mass. In cultured neonatal rat myocardial myoblasts, cellular protein content and cell size increased when sodium concentration of the medium was augmented (15). In vivo, a high-sodium intake increased cardiac mass in normotensive rats (46) and exacerbated cardiac hypertrophy in hypertensive rats (12). In humans, sodium intake (assessed by urinary sodium excretion) and the left ventricular mass index were positively correlated in hypertensive and normotensive subjects (9). Conversely, a low-sodium (LS) intake prevents cardiac hypertrophy associated with two-kidney, one-clip Goldblatt hypertension (5, 26, 32, 36, 41) and ANG II hypertension (27). The beneficial effect of dietary sodium restriction on cardiac mass may parallel the change in arterial pressure (5, 41) or can be independent of arterial pressure reduction (26, 27, 32).
Aside from a direct effect on arterial pressure and cardiac mass, ANG
II and sodium intake may alter the cardiovascular system through an
increased production of reactive oxygen species (19). ANG
II induces an overexpression of cytosolic proteins involved in the
activation of NAD(P)H oxidase of vascular endothelial and smooth muscle
cells (13, 43) and favors the production of reactive
oxygen species, such as superoxide anion (O
In the present study, we tested the hypothesis that severe and chronic dietary sodium restriction may reduce the prooxidant effect of ANG II and prevent the development of cardiac and renal alterations associated with long-term infusion of the peptide. The dose of ANG II was doubled in sodium-restricted rats to obtain a level of hypertension similar to that achieved in sodium-replete rats infused with the low dose of the peptide. The present results indicate that cardiac hypertrophy, albuminuria, and hyperproduction of reactive forms of oxygen associated with ANG II hypertension are prevented by dietary sodium restriction independently of arterial pressure reductions.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
The experiments were carried out in 6 groups of 16 Sprague-Dawley rats (Iffa-Credo; L'Arbresle, France) maintained on a
normal sodium (NS) or LS diet. LS rats weighed 200-220 g at the
beginning of studies and NS rats were matched to obtain a similar body
weight before ANG II infusion. The LS diet consisted of a sodium-free rat chow containing <5 mmol sodium/kg and distilled water as drinking fluid. The NS diet was obtained by the addition of 8.7 g NaCl/kg of the food. The sodium content of the diet was modified at least 3 wk
before ANG II infusion to allow the animals to reach a new sodium
balance. Rats were then placed in individual metabolic cages until the
end of experiments. After a 3-day control period, ANG II (Sigma; Paris,
France) was infused subcutaneously via osmotic pumps (model 2002, Alza;
Palo Alto, CA) at the dose of 200 or 400 ng · kg
1 · min
1
for 10 days in rats maintained on the NS and LS diet. Two groups of
rats were infused with distilled water and served as control animals.
Before and during ANG II infusion, body weight, food and water intake, and urinary excretion of water, sodium, and potassium were measured daily in all rats. Urinary excretion of albumin and creatinine was determined before and at the end of treatment period. Tail-cuff pressure (TCP; Narco Biosystems, Houston, TX) was recorded in conscious rats before and every second day of the experimental period. On day 10 of ANG II infusion, groups were split into two subgroups of eight rats and prepared either for cardiac output and renal blood flow determination or measurement of tissue production of reactive forms of oxygen. All procedures were designed in accordance with French law and institutional guidelines for the care and use of laboratory animals.
Cardiac output and renal blood flow. Cardiac output and renal blood flow were evaluated in conscious rats using 57Co-labeled microspheres (15 ± 1 mm diameter; New England Nuclear Research Products; Boston, MA). Three hours after implantation under ether anesthesia, the left ventricular and femoral arterial catheters were connected to a pressure transducer, and arterial pressure and heart rate were continuously recorded for 30 min. During the intraventricular injection of microspheres, blood was sampled at the rate of 0.5 ml/min for 2 min for radioactivity counting and determination of plasma concentrations of sodium, potassium, and creatinine. At the end of experiments, the heart and the kidneys were removed and weighed for radioactivity counting. The heart weight index (HWI) and kidney weight index were calculated as the ratio of the heart or kidney to body weight (BW, in mg/g) in the 96 rats included in this study.
Detection of reactive oxygen species.
Production of O


Analytical methods and statistical analysis. Plasma and urine concentrations of sodium and potassium were measured by flame photometry (Corning), and plasma concentration of creatinine was estimated by the colorimetric method (Beckman). Creatinine clearance at the end of experiments was calculated. Urinary excretion of albumin was determined by the immunonephelemetric method (33).
Results are expressed as means ± SE and were analyzed by one-factor or two-factor analysis of variance for repeated measures when appropriate. Differences between groups were assessed by the Bonferroni's test. Within-group differences were evaluated by the Student's t-test for paired values. Slopes of the linear regression between final TCP and HWI were compared with the use of Wald's test. A P value of <0.05 was considered statistically significant.| |
RESULTS |
|---|
|
|
|---|
Arterial pressure.
As depicted in Fig. 1, TCP was similar
and remained stable throughout studies in the control rats fed either
diet. Infusion of the low dose of ANG II induced a rise in TCP in all
rats; however, the final level of TCP was significantly lower in the LS
than NS rats (157 ± 3 vs. 171 ± 6 mmHg, respectively). When
the high dose of ANG II was given, final TCP was slightly and not
significantly lower in the LS than NS rats (178 ± 4 and 189 ± 10 mmHg, respectively). Interestingly, the final value of TCP was
similar in the LS group infused with the high dose of ANG II and the NS
rats infused with the low dose of ANG II (Fig.
2).
|
|
Cardiac mass.
As shown in Fig. 2, HWI was similarly increased by the low and high
dose of ANG II in sodium-replete rats compared with their NS controls
(3.48 ± 0.10 and 3.53 ± 0.11 vs. 2.97 ± 0.04 mg/g BW,
respectively, P < 0.01). In the LS rats, neither the
low nor the high dose of ANG II had a significant effect on HWI
compared with control LS rats (2.72 ± 0.04 and 2.90 ± 0.04 vs. 2.67 ± 0.04 mg/g BW, respectively). Moreover, HWI remained
lower than normotensive NS control rats in hypertensive LS rats. Of
note, HWI was lower in control rats fed the sodium-free diet compared
with the control NS rats (2.67 ± 0.04 vs. 2.97 ± 0.04 mg/g
BW, P < 0.01). In fact, HWI was positively correlated
with the final level of TCP (Fig. 3) and
the slope of the regression line was lower in LS than NS rats
(44.2 ± 1.12 vs. 89.9 ± 1.8 × 10
4
mg · g
1 · mmHg
1,
P < 0.001).
|
Metabolic parameters.
Body weight was similar in all rats before ANG II infusion. Within the
10-day period of observation, body weight gain was lower in LS than NS
rats. The development of ANG II hypertension was associated with a
reduction of body growth in both regimens, the high dose of ANG II
inhibiting weight gain in LS rats (Table 1). As shown in Table 1, food intake was
similar in NS and LS rats infused with the low dose of ANG II or its
vehicle. However, food consumption was reduced in both regimens when
the peptide was given at the high dose.
|
Systemic and renal hemodynamics.
At the end of experiments, mean arterial pressure determined in
conscious rats was similarly increased in NS and LS rats infused with
ANG II (Table 2). Cardiac output and
renal blood flow were lower, and total peripheral and renal vascular
resistances were higher in the LS than in NS control rats, although the
level of significance was not achieved. ANG II infusion was associated with a rise in total and renal resistances and with a reduction in
cardiac output and renal blood flow in both sodium regimens. The
systemic and renal effects of ANG II were similar for the two doses
used in the present study.
|
Urinary excretion of albumin.
As depicted in Fig. 4, basal urinary
excretion of albumin was similar in all groups and remained stable
throughout the studies in control NS and LS rats. The marked rise in
albuminuria associated with infusion of the low dose of ANG II in NS
rats was prevented by sodium depletion. When the dose of ANG II was
doubled, albuminuria rose in LS rats, but remained lower than their
corresponding hypertensive NS rats and comparable to that obtained in
the NS rats infused with the low dose of ANG II.
|
Production of reactive oxygen species.
O


|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, it was demonstrated that severe dietary sodium restriction prevented the development of cardiac hypertrophy associated with ANG II, despite the achievement of a similar level of hypertension obtained by adjusting the dose of the peptide infused. In addition, the ANG II-induced rise in albuminuria was blunted in sodium-restricted rats. Interestingly, the increase of reactive oxygen species production by the heart and aorta in rats infused with ANG II was also prevented by prior dietary sodium restriction.
Prevention by sodium restriction of the increase in cardiac mass was
accompanied by a slight attenuation of ANG II hypertension compared
with rats fed the regular sodium diet. The reduced responsiveness to
the peptide may be related to a downregulation of ANG II type 1 receptors (1) and/or unopposed vasodilatation mediated by the type 2 receptors, as reported in normotensive rats
(35). Although we cannot exclude the involvement of blood
pressure changes in the prevention of cardiac hypertrophy by sodium
restriction, several reports favor the hypothesis of a
pressure-independent influence of dietary sodium removal on cardiac
mass. In two-kidney, one-clip hypertension, a severe sodium restriction
prevented cardiac growth in the absence of significant antihypertensive
influences (23, 32). In ANG II hypertension, cardiac
hypertrophy was also prevented without a change in blood pressure in
rats submitted to a moderate sodium restriction (27). In
addition, dietary sodium restriction initiated during the established
phase of renovascular hypertension had no effect on blood pressure but
reversed cardiac hypertrophy (36). In the present study,
the dose of ANG II was doubled (400 ng · kg
1 · min
1)
in sodium-depleted rats to achieve a similar level of hypertension in
both sodium regimen groups. In these conditions of similar development
and final level of hypertension and higher ANG II infusion rate, sodium
restriction still precluded the increase in cardiac mass. In addition,
the kidney weight index was similar in all groups, thus suggesting that
the effect of the low sodium intake specifically affected cardiac
growth. Although we cannot exclude its involvement in the cardiac
effect of the LS diet, the lower rate of body growth had probably only
a minor role, if any. With the use of a similar protocol, cardiac
hypertrophy induced by the low dose of ANG II was almost totally
prevented (HWI was 3.16 ± 0.07, n = 12) in rats
fed the LS diet supplemented with a minimal amount of sodium (~700
µmoles per day) that allows normal body weight gain (B. Jover, C. Rugale, and A. Mimran, unpublished observations).
Interestingly, cardiac mass index was also reduced by sodium
restriction in normotensive rats. A comparable finding was previously
reported in sham-operated rats of the two-kidney, one-clip hypertension
(5). In fact, the slope of the linear correlation between
cardiac mass index and arterial pressure was blunted by dietary sodium
restriction as illustrated in Fig. 3. Therefore, sodium intake appears
as an important modulator of cardiac mass independently of the level
and changes of arterial pressure.
Beside changes in pressure overload, the beneficial effect of dietary sodium restriction on cardiac mass may be related to a reduction of preload of the heart. In sodium-replete rats, infusion of the low dose of ANG II was associated with an increase in sodium and water balances. Interestingly, such changes did not occur in the LS rats, thus suggesting that prevention of the increase in circulating volume may participate in the beneficial influence of dietary sodium removal on cardiac structure. When given at the high dose, ANG II was associated with a reduction of water balance and achievement of a negative sodium balance in sodium-replete rats. Such a loss of sodium may represent a malignant form of hypertension, or, more likely, it may reflect the activation of the pressure-natriuresis mechanism, which is altered in ANG II hypertension (38). Despite this sodium wasting state, cardiac hypertrophy developed in NS rats but not in LS rats, a finding that does not favor a major role for preload changes in the antihypertrophic effect of sodium restriction in the present model. In addition, it was previously reported that severe sodium restriction prevented the development of cardiac hypertrophy in two-kidney, one-clip hypertension without change in sodium and water balances (32).
Together with the increase in arterial pressure and cardiac mass, both doses of ANG II induced a marked rise in urinary albumin excretion as well as glomerular filtration rate, equated with creatinine clearance, in rats fed the NS diet. Previous studies have implicated an increase in glomerular capillary pressure in the proteinuria associated with ANG II hypertension (25) and 5/6 nephrectomy (18). Severe dietary sodium restriction, a maneuver devoid of effect on hypertension and renal vasoconstriction, prevented both the proteinuric effect and hyperfiltration associated with infusion of the low dose of ANG II in the present study. When the dose of ANG II was doubled, albuminuria rose in rats fed the sodium-free diet without change in glomerular filtration rate. However, albuminuria was lower in sodium-depleted than in sodium-replete rats infused with a high dose of ANG II. These results do not favor a major role of the blunting of hyperfiltration in the beneficial effect of dietary sodium restriction on proteinuria. Similar prevention of proteinuria by dietary sodium restriction was previously described in uninephrectomized spontaneously hypertensive rats (3) and 5/6 nephrectomy model (10). In the latter studies (3, 10), it was clearly shown that reduction in glomerular pressure determined by micropuncture or arterial pressure did not account for the beneficial effect of sodium restriction.
The beneficial effects of dietary sodium restriction are probably
multifactorial with complex interactions between various systems such
as the renin-angiotensin-aldosterone system, the sympathetic nervous
system, endothelin, prostaglandins, or the nitric oxide system. Beside
the hormonal systems, the redox status of the cell has been evoked as a
potential mechanism of the cardiovascular alterations associated with
hypertension and/or high-sodium intake. It was demonstrated that
reactive oxygen species are responsible for the functional changes in
the microcirculation of rats fed a high-salt diet (20,
21). In Dahl salt-sensitive rats, it was reported that the
antioxidant capacity was reduced in rats on a normal sodium diet and
worsened when salt intake was increased (22). However, the
influence of a reduced intake of sodium on oxidative stress has not
been investigated. The major goal of the present study was to evaluate
the effect of dietary sodium restriction on the stimulation by ANG II
of the production of reactive oxygen species in the heart and arterial
wall of hypertensive rats. As previously described, ANG II infusion was
associated with a rise in the production of reactive forms of oxygen
(19, 42). A prominent finding of our study is the complete
prevention of the prooxidant effect of the octapeptide in rats fed the
sodium-restricted diet. Particularly, sodium restriction prevented the
hyperproduction of O

| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by the Ministère de la Recherche, Contrat Quadriennal 1999-2002. C. Rugale was the recipient of a scholarship from the Fédération Française de Cardiologie.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: B. Jover, Institut Universitaire de Recherche Clinique, Groupe Rein et Hypertension, 641 Av du Doyen Gaston Giraud, 34 093 Montpellier Cedex 5, France (E-mail: jover{at}iurc.montp.inserm.fr).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 5, 2002;10.1152/ajpheart.00864.2002
Received 4 October 2002; accepted in final form 26 November 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aguilera, G,
and
Catt K.
Regulation of vascular angiotensin II receptors in the rats during altered sodium intake.
Circ Res
49:
751-758,
1981
2.
Baker, KM,
and
Aceto JF.
Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells.
Am J Physiol Heart Circ Physiol
259:
H610-H618,
1990
3.
Beinstein, JA,
Feiner HD,
Parker M,
and
Dworkin LD.
Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR.
Am J Physiol Renal Fluid Electrolyte Physiol
258:
F1675-F1681,
1990
4.
Crawford, DC,
Chobanian AV,
and
Brecher P.
Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat.
Circ Res
74:
727-739,
1994
5.
De Simone, G,
Devereux RB,
Camargo MJF,
Wallerson DC,
and
Laragh JH.
Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension.
Am J Physiol Heart Circ Physiol
264:
H2103-H2110,
1993
6.
Delbosc, S,
Cristol JP,
Descomps B,
Mimran A,
and
Jover B.
Simvastatin prevents angiotensin II-induced cardiac alterations and oxidative stress.
Hypertension
40:
142-147,
2002
7.
Dostal, DE,
and
Baker KM.
Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT1 receptor.
Am J Hypertens
5:
276-280,
1992[Web of Science][Medline].
8.
Drayer, J,
Weber MA,
and
De Young DL.
Blood pressure as a determinant of cardiac left ventricular muscle mass.
Arch Intern Med
142:
90-92,
1983.
9.
Du Cailar, G,
Ribstein J,
Daures JP,
and
Mimran A.
Sodium and left ventricular mass in untreated hypertensive and normotensive subjects.
Am J Physiol Heart Circ Physiol
263:
H177-H181,
1992
10.
Dworkin, LD,
Benstein JA,
Tolbert E,
and
Feiner HD.
Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease.
J Am Soc Nephrol
7:
437-442,
1996[Abstract].
11.
Ferdinandy, P,
Danial H,
Ambrus I,
Rothery RA,
and
Schulz R.
Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure.
Circ Res
87:
241-247,
2000
12.
Frohlich, ED,
Chien Y,
Sesoko S,
and
Pergam BL.
Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats.
Am J Physiol Regul Integr Comp Physiol
264:
R30-R34,
1993
13.
Griendling, KK,
Mineiri CA,
Ollerenshaw JD,
and
Alexander RW.
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Circ Res
74:
1141-1148,
1994
14.
Griffin, SA,
Brown WCB,
MacPherson F,
McGrath JC,
Wilson VG,
Korsgaard N,
Mulvany MJ,
and
Lever AF.
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
Hypertension
17:
626-635,
1991
15.
Gu, JW,
Anand V,
Shek EW,
Moore MC,
Brady AL,
Kelly WC,
and
Adair TH.
Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscles cells.
Hypertension
31:
1083-1087,
1998
16.
Hannken, T,
Schroeder R,
Stahl RAK,
and
Wolf G.
Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals.
Kidney Int
54:
1923-1933,
1998[Web of Science][Medline].
17.
Herizi, A,
Jover B,
Bouriquet N,
and
Mimran A.
Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade.
Hypertension
31:
10-14,
1998
18.
Hostetter, TH,
Olson JL,
Rennke HG,
Venkatachalam MA,
and
Brenner BM.
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.
Am J Physiol Renal Fluid Electrolyte Physiol
241:
F85-F93,
1981
19.
Laursen, JB,
Rajagopalan S,
Galis Z,
Tarpey M,
Freeman BA,
and
Harrison DG.
Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension.
Circulation
95:
588-593,
1997
20.
Lenda, DM,
and
Boegehold MA.
Effect of a high-salt diet on oxidant enzyme activity in skeletal muscle microcirculation.
Am J Physiol Heart Circ Physiol
282:
H395-H402,
2002
21.
Lenda, DM,
Sauls BA,
and
Boegehold MA.
Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt.
Am J Physiol Heart Circ Physiol
279:
H7-H14,
2000
22.
Li, S,
Nadar A,
Gregory M,
and
Khan N.
Antioxidant status of the hypertrophic heart of Dahl hypertensive rat as a model for evaluation of antioxidants.
Methods Find Exp Clin Pharmacol
23:
5-12,
2001[Web of Science][Medline].
23.
Lindpaintner, K,
and
Sen S.
Role of sodium in hypertensive cardiac hypertrophy.
Circ Res
57:
610-617,
1985
24.
Lyall, F,
Morton JJ,
Lever AF,
and
Cargoe EJ.
Angiotensin II activates Na+/H+ exchange and stimulates growth in cultured vascular smooth muscle cells.
J Hypertension
6, Suppl4:
S438-S441,
1988.
25.
Miller, PL,
Rennke HG,
and
Meyer TW.
Glomerular hypertrophy accelerates hypertensive glomerular injury in rats.
Am J Physiol Renal Fluid Electrolyte Physiol
261:
F459-F465,
1991
26.
Morgan, T,
Aubert JF,
and
Brunner H.
Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy.
Am J Hypertens
14:
914-920,
2001[Web of Science][Medline].
27.
Morgan, TO,
Aubert JF,
and
Wang Q.
Sodium, angiotensin II, blood pressure, and cardiac hypertrophy.
Kidney Int
54, Suppl67:
S213-S215,
1998[Web of Science].
28.
Nakamura, K,
Fushimi K,
Kouchi H,
Mihara K,
Miyazaki M,
Ohe T,
and
Namba M.
Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-
and angiotensin II.
Circulation
98:
798-799,
1998.
29.
Nishiyama, A,
Fukui T,
Fujisawa Y,
Rahman M,
Tian RX,
Kimura S,
and
Abe Y.
Systemic and regional hemodynamic response to tempol in angiotensin II-infused hypertensive rats.
Hypertension
37:
77-83,
2001
30.
Ortiz, MC,
Manriquez MC,
Romero JC,
and
Juncos LA.
Antioxidants block angiotensin II-induced increases in blood pressure and endothelin.
Hypertension
38:
655-659,
2001
31.
Park, JK,
Müller DN,
Mervaala EMA,
Dechend R,
Fiebeler A,
Schmidt F,
Bieringer M,
Schäfer O,
Lindschau C,
Schneider W,
Ganten D,
Luft FC,
and
Haller H.
Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Kidney Int
58:
1420-1430,
2000[Web of Science][Medline].
32.
Pasquié, JL,
Jover B,
du Cailar G,
and
Mimran A.
Sodium but not chloride ion modulates left ventricular hypertrophy in two-kidney, one clip hypertension.
J Hypertens
12:
1013-1018,
1994[Web of Science][Medline].
33.
Redon, J,
Baldo E,
Lubre E,
Bertolin V,
Lozano JV,
Miralles A,
and
Pascual JM.
Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension.
Kidney Int
49, Suppl55:
S81-S84,
1996.
34.
Sadoshima, JI,
and
Izumo S.
Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
Circ Res
73:
413-423,
1993
35.
Scheuer, DA,
and
Perrone MH.
Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin II.
Am J Physiol Regul Integr Comp Physiol
264:
R917-R923,
1993
36.
Sen, S,
and
Young DR.
Role of sodium in modulation of myocardial hypertrophy in renal hypertensive rats.
Hypertension
8:
918-924,
1986
37.
Susic, D,
Nunez E,
Frohlich ED,
and
Prakash O.
Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs.
Hypertension
28:
265-268,
1996
38.
Van Der Mark, J,
and
Kline RL.
Altered pressure natriuresis in chronic angiotensin II hypertension in rats.
Am J Physiol Regul Integr Comp Physiol
266:
R739-R748,
1994
39.
Wang, HD,
Hope S,
Du Y,
Quinn MT,
Cayatte A,
Pagano PJ,
and
Cohen RA.
Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension.
Hypertension
33:
1225-1232,
1999
40.
Wang, HD,
Xu S,
Johns DG,
Du Y,
Quinn MT,
Cayatte AJ,
and
Cohen RA.
Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice.
Circ Res
88:
947-953,
2001
41.
Wilczynski, EA,
Yuan B,
and
Leenen FHH
Dietary sodium restriction and the development of two-kidney, one-clip hypertension in young versus adult rats.
Can J Physiol Pharmacol
70:
452-457,
1992[Web of Science][Medline].
42.
Wilson, SK.
Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat.
Circ Res
66:
722-734,
1990
43.
Wolf, G.
Free redical production and angiotensin.
Curr Hypertens Rep
2:
167-173,
2000[Medline].
44.
Wright, J,
Maridonneau-Parini I,
Cragoe EJ, Jr,
Schwartz JH,
and
Tauber AI.
The role of Na+/H+ antiporter in human neutrophil NADPH-oxidase activation.
J Leukoc Biol
43:
183-186,
1988[Abstract].
45.
Xie, YW,
and
Wolin MS.
Role of nitric oxide and its interaction with superoxide in the suppresion of cardiac muscle mitochondrial respiration.
Circulation
94:
2580-2586,
1996
46.
Yuan, B,
and
Leenen FHH
Dietary sodium intake and left ventricular hypertrophy in normotensive rats.
Am J Physiol Heart Circ Physiol
261:
H1397-H1401,
1991
This article has been cited by other articles:
![]() |
C. D. Garciarena, C. I. Caldiz, E. L. Portiansky, G. E. Chiappe de Cingolani, and I. L. Ennis Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart J Appl Physiol, April 1, 2009; 106(4): 1325 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hou, K. Okada, C. Okamoto, S. Ueshima, and O. Matsuo Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodeling Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1257 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Cingolani and I. L. Ennis Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy Circulation, March 6, 2007; 115(9): 1090 - 1100. [Full Text] [PDF] |
||||
![]() |
U. K. Dutta, J. Lane, L. J. Roberts II, and D. S. A. Majid Superoxide formation and interaction with nitric oxide modulate systemic arterial pressure and renal function in salt-depleted dogs. Experimental Biology and Medicine, March 1, 2006; 231(3): 269 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cordaillat, C. Rugale, D. Casellas, A. Mimran, and B. Jover Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1137 - R1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rugale, M. Cordaillat, A. Mimran, and B. Jover Prevention and Reversal by Enalapril of Target Organ Damage in Angiotensin II Hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 154 - 160. [Abstract] [PDF] |
||||
![]() |
E. Ritz and V. Haxsen Angiotensin II and Oxidative Stress: An Unholy Alliance J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2985 - 2987. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |